Incidental ferumoxytol artifacts in clinical brain MR imaging

• Published in: Neuroradiology 2016-11, Vol.58 (11), p.1087-1091
• Main Authors: Bowser, Bruce A., Campeau, Norbert G., Carr, Carrie M., Diehn, Felix E., McDonald, Jennifer S., Miller, Gary M., Kaufmann, Timothy J.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anemia; Brain; Brain - diagnostic imaging; Brain - drug effects; Contrast Media - administration & dosage; Diagnostic Neuroradiology; Ferrosoferric Oxide - administration & dosage; Humans; Imaging; Incidental Findings; Injections, Intravenous; Magnetic Resonance Imaging - methods; Male; Medical errors; Medicine; Medicine & Public Health; Middle Aged; Neurology; Neuroradiology; Neurosciences; Neurosurgery; NMR; Nuclear magnetic resonance; Parenteral nutrition; Radiology; Reproducibility of Results; Sensitivity and Specificity
• ISSN: 0028-3940; 1432-1920
• DOI: 10.1007/s00234-016-1747-1

Introduction Ferumoxytol (Feraheme) is a parenteral therapy approved for treatment of iron deficiency anemia. The product insert for ferumoxytol states that it may affect the diagnostic ability of MRI for up to 3 months. However, the expected effects may not be commonly recognized among clinical neuroradiologists. Our purpose is to describe the artifacts we have seen at our institution during routine clinical practice. Methods We reviewed the patients at our institution that had brain MRI performed within 90 days of receiving intravenous ferumoxytol. The imaging was reviewed for specific findings, including diffusion-weighted imaging vascular susceptibility artifact, gradient-echo echo-planar T2*-weighted vascular susceptibility artifact, SWI/SWAN vascular susceptibility artifact, hypointense vascular signal on T2-weighted images, pre-gadolinium contrast vascular enhancement on magnetization-prepared rapid acquisition gradient echo (MPRAGE) imaging, and effects on post-gadolinium contrast T1 imaging. Results Multiple artifacts were observed in patients having a brain MRI within 3 days of receiving intravenous ferumoxytol. These included susceptibility artifact on DWI, GRE, and SWAN/SWI imaging, pre-gadolinium contrast increased vascular signal on MPRAGE imaging, and decreased expected enhancement on post-gadolinium contrast T1-weighted imaging. Conclusion Ferumoxytol can create imaging artifacts which complicate clinical interpretation when brain MRI is performed within 3 days of administration. Recognition of the constellation of artifacts produced by ferumoxytol is important in order to obviate additional unnecessary examinations and mitigate errors in interpretation.